Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04089-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Xiaowen Cui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immune Checkpoint Inhibitors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Plan of Shanghai Hospital Development Center, Program of Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Resistance limits the efficacy and durability of immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC). Therefore, we conducted a retrospective cohort study to investigate the outcomes and characteristics of HCC patients with resistance to immunotherapy. Patients with HCC who have received ICIs at Eastern Hepatobiliary Surgery Hospital between 2016 and 2021 were retrospectively screened and divided into primary resistance, secondary resistance, and durable response group. Time to progression (TTP), overall survival (OS), subsequent management and post-progression survival (PPS) were analyzed. Of 496 patients included, 229 (46.2%) and 141 (28.4%) patients developed primary and secondary resistance, and 126 (25.4%) patients achieved a durable response, the median TTP was 2.83 [2.56–3.09] months, 11.93 [10.45–13.40] months, and not reached, respectively, whereas the median OS was 12.83 [10.36–15.30] months, 31.53 [28.09–34.97] and not reached, respectively. Multivariate logistic regression revealed that Child–Pugh score, BCLC stage, and combined systemic therapies (ICI plus bevacizumab or lenvatinib versus ICI monotherapy) were independently associated with primary resistance, and only combined systemic therapies (ICI plus bevacizumab versus ICI monotherapy) were independently associated with secondary resistance. AFP levels were independently associated with PPS in patients with primary resistance, while post-progression therapies (ICI-based therapies versus others) were independently associated with PPS in patients with resistance. The risk of resistance was notably lower in patients receiving the combination of ICI plus bevacizumab. High AFP levels were associated with the survival of patients with primary resistance. ICI-based maintenance therapy after resistance may provide a significant survival advantage for HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, Shanghai, China.
- The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, 225 Changhai Road, Shanghai, 200438, China.
- Department of Special Treatment I and Liver Transplantation, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, Shanghai, China.
- National Center for Liver Cancer, The Naval Medical University, 800 Xiangyin Road, Shanghai, 200433, China. sunwen_sw@aliyun.com.
- The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Naval Medical University, 225 Changhai Road, Shanghai, 200438, China. wangruoyu1213@126.com.
Förderung
- National Natural Science Foundation of China
- Clinical Research Plan of Shanghai Hospital Development Center
- Program of Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Cui, X., Ruan, M., Li, Y., Yang, C., Zhang, J., Jin, R., Wu, D., Sun, W., & Wang, R. (2025). Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04089-x
Vancouver
Cui X, Ruan M, Li Y, Yang C, Zhang J, Jin R, et al. Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04089-x
BibTeX
@article{Cui2025,
author = {Cui, Xiaowen and Ruan, Minghao and Li, Yao and Yang, Cheng and Zhang, Jin and Jin, Riming and Wu, Dong and Sun, Wen and Wang, Ruoyu},
title = {Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04089-x}
}
EUVIMED